» Articles » PMID: 12142752

Expression of Integrin AlphaVbeta3 in Pancreatic Carcinoma: Relation to MMP-2 Activation and Lymph Node Metastasis

Overview
Journal Pancreas
Specialty Gastroenterology
Date 2002 Jul 27
PMID 12142752
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Overexpression of integrin alphaVbeta3 had been demonstrated in various tumors. Studies have suggested that elevated levels of integrin alphaVbeta3 in melanoma cells are deeply involved in the mechanism of increased melanoma invasiveness.

Aims: To examine the expression of integrin alphaVbeta3 in pancreatic carcinoma and to evaluate the correlation between integrin expression accompanied by MMP-2 activation and clinicopathologic factors.

Methodology: Integrin alphaVbeta3 specific antibody LM-609 was used for immunochemical analysis, and intracellular localization was determined in human pancreatic cancer cell lines cultured on vitronectin coating. Fifty pancreatic adenocarcinomas analyzed immunohistochemically and 26 frozen samples were analyzed gelatin-zymographically.

Results: Two of three pancreatic cancer cell lines demonstrated integrin alphaVbeta3 immunofluorescence with a membranous pattern, and 29 of 50 pancreatic carcinomas showed positive immunostaining of tumor cells. There was no significant correlation between integrin alphaVbeta3 expression and tumor size, tumor grade, or peripancreatic invasion. However, primary tumors with lymph node metastasis featured significantly higher expression of integrin alphaVbeta3 than those without node metastasis. Tumors with high integrin alphaVbeta3 expression showed significantly higher MMP-2 activation ratios than did tumors with low expression.

Conclusion: Expression analysis in pancreatic cancer tissue demonstrated involvement of alphaVbeta3 integrin in lymph node metastasis rather than peripancreatic invasion. MMP-2 activation is linked, at least in part, to the expression of integrin alphaVbeta3 of pancreatic cancer cells.

Citing Articles

Long-Term Therapeutic Effects of Ac-DOTA-E[c(RGDfK)] Induced by Radiosensitization via G2/M Arrest in Pancreatic Ductal Adenocarcinoma.

Yoshimoto M, Washiyama K, Ohnuki K, Doi A, Inokuchi M, Kojima M Pharmaceutics. 2025; 17(1).

PMID: 39861661 PMC: 11768328. DOI: 10.3390/pharmaceutics17010009.


αvβ3 integrin-targeted magnetic resonance imaging in a pancreatic cancer mouse model using RGD-modified liposomes encapsulated with Fe-deferoxamine.

Yoshimoto M, Hayakawa T, Yamaguchi M, Kimura S, Fujii H PLoS One. 2024; 19(9):e0310984.

PMID: 39316565 PMC: 11421790. DOI: 10.1371/journal.pone.0310984.


MR Molecular Image Guided Treatment of Pancreatic Cancer with Targeted ECO/miR-200c Nanoparticles in Immunocompetent Mouse Tumor Models.

Laney V, Hall R, Yuan X, Hampson E, Halle A, Yeung G Pharm Res. 2024; 41(9):1811-1825.

PMID: 39198318 PMC: 11436418. DOI: 10.1007/s11095-024-03762-7.


Expression of integrin αβ in medullary thyroid carcinoma.

de Vries L, Lodewijk L, Pijnappel E, van Diest P, Schepers A, Bonenkamp H Future Oncol. 2024; 20(27):2015-2022.

PMID: 39101553 PMC: 11497997. DOI: 10.1080/14796694.2024.2376511.


Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer.

Gu X, Minko T Cancers (Basel). 2024; 16(8).

PMID: 38672671 PMC: 11048786. DOI: 10.3390/cancers16081589.